PharmaPoint: Colorectal Cancer – Global Drug Forecast and Market Analysis to 2023

Pages: 346 Published: November 01, 2014 Report Code: GDHC95PIDR

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • Listen
    Convert Text to Speech

Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended. The CRC market is expected to grow due to the incorporation of five late-stage pipeline agents during the forecast period, including Mologen’s MGN1703, Eli Lilly’s Cyramza, and Boehringer Ingelheim’s nintedanib. Furthermore, GlobalData expects the label extension of Stivarga as a first-line adjuvant treatment for metastatic CRC patients with resected liver metastases. Ultimately, however, GlobalData expects unmet needs to remain unfulfilled by these pipeline agents, and anticipates that novel, innovative approaches, such as those targeting BRAF mutation-positive disease and immune checkpoint inhibitors, will provide the best opportunity for substantial improvement in the prognosis of advanced CRC patients.

Scope

Overview of colorectal cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized Colorectal cancer therapeutics market revenue, annual cost of therapy, and treatment usage patterns in eight patient segments, forecast from 2013 to 2023.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, remaining commercial opportunities, and current and future players for the colorectal cancer therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidates in Phase III development are profiled.

Analysis of the current and future market competition in the global colorectal cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

What are the corporate strategies being used by drug makers?

How is the disease management evolving? What is the impact for drug manufacturers?

What opportunities remain after the launch of pipeline agents?

How large are the metastatic KRAS wild-type and mutation-positive CRC markets for branded agents, and which are growing the fastest?

What exciting, innovative approaches are being investigated in CRC? Which immunotherapies are of interest to the CRC market?

What do KOLs think about the latest therapies and drug development strategies?

Key Players

Alchemia

AstraZeneca

Bayer

Biothera

Bristol-Myers Squibb

Boehringer Ingelheim

Eli Lilly & Company

GlaxoSmithKline

Merck & Co

Merck KGaA

Mologen AG

Novartis

Onyx

Regeneron

Roche

Sanofi

Taiho Pharmaceuticals

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.2Clinical Staging

3.3Symptoms

4Epidemiology

4.1Disease Background

4.2Risk Factors and Comorbidities

4.3Global Trends

4.3.18MM, Incidence Trends

4.3.28MM, Five-Year Relative Survival

4.3.38MM, Screening Programs for CRC

4.4Forecast Methodology

4.4.1Sources Used

4.4.2Sources Not Used

4.4.3Forecast Assumptions and Methods

4.5Epidemiological Forecast of CRC (2013–2023)

4.5.1Diagnosed Incident Cases of CRC

4.5.2Age-Specific Diagnosed Incident Cases of CRC

4.5.3Sex-Specific Diagnosed Incident Cases of CRC

4.5.4Age-Standardized Incidence

4.5.5Cancer Stage at Diagnosis

4.5.6Diagnosed Five-Year Prevalent Cases of CRC

4.5.7KRAS Status among Diagnosed Five-Year Prevalent Cases of CRC

4.6Discussion

4.6.1Epidemiological Forecast Insight

4.6.2Limitations of the Analysis

4.6.3Strengths of the Analysis

5Disease Management

5.1Diagnosis and Treatment Overview

5.1.1Screening and Diagnosis

5.1.2Treatment Guidelines and Leading Prescribed Drugs

5.1.3Clinical Practice

5.2US

5.2.1Screening and Diagnosis

5.2.2Clinical Practice

5.3France

5.3.1Screening and Diagnosis

5.3.2Clinical Practice

5.4Germany

5.4.1Screening and Diagnosis

5.4.2Clinical Practice

5.5Italy

5.5.1Screening and Diagnosis

5.5.2Clinical Practice

5.6Spain

5.6.1Screening and Diagnosis

5.6.2Clinical Practice

5.7UK

5.7.1Screening and Diagnosis

5.7.2Clinical Practice

5.8Japan

5.8.1Screening and Diagnosis

5.8.2Clinical Practice

5.9China

5.9.1Screening and Diagnosis

5.9.2Clinical Practice

6Competitive Assessment

6.1Overview

6.2Product Profiles — Major Brands

6.2.1Avastin (Bevacizumab)

6.2.2Erbitux (Cetuximab)

6.2.3Vectibix (Panitumumab)

6.2.4Stivarga (Regorafenib)

6.2.5Zaltrap (Ziv-Aflibrcept)

6.2.6Lonsurf (TAS-102)

6.2.7TS-1 (Tegafur, Gimeracil, Oteracil)

6.2.8Xeloda (Capecitabine)

7Unmet Need and Opportunity

7.1Overview

7.2Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients

7.2.1Unmet Need

7.2.2Gap Analysis

7.2.3Opportunity

7.3Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients

7.3.1Unmet Need

7.3.2Gap Analysis

7.3.3Opportunity

7.4Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease

7.4.1Unmet Need

7.4.2Gap Analysis

7.4.3Opportunity

7.5Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients

7.5.1Unmet Need

7.5.2Gap Analysis

7.5.3Opportunity

8Pipeline Assessment

8.1Overview

8.2Promising Drugs in Clinical Development

8.2.1Cyramza (Ramucirumab)

8.2.2Imprime PGG

8.2.3MGN1703

8.2.4Nintedanib (BIBF-1120)

8.3Promising Approaches in Early-Stage Development

8.3.1Anti-Angiopoietin-2 Inhibitors

8.3.2Strategies for BRAF Mutation-Positive Disease

8.3.3Strategies for KRAS-Mutation Positive Disease

8.3.4Immune Checkpoint Inhibitors

9Current and Future Players

9.1Overview

9.2Trends in Corporate Strategy

9.3Company Profiles

9.3.1Roche/Genentech

9.3.2Sanofi

9.3.3Eli Lilly and Company

9.3.4Merck KGaA

9.3.5Bayer

9.3.6Taiho Pharmaceutical

10Market Outlook

10.1Global Markets

10.1.1Forecast

10.1.2Drivers and Barriers – Global Issues

10.2United States

10.2.1Forecast

10.2.2Key Events

10.2.3Drivers and Barriers

10.3France

10.3.1Forecast

10.3.2Key Events

10.3.3Drivers and Barriers

10.4Germany

10.4.1Forecast

10.4.2Key Events

10.4.3Drivers and Barriers

10.5Italy

10.5.1Forecast

10.5.2Key Events

10.5.3Drivers and Barriers

10.6Spain

10.6.1Forecast

10.6.2Key Events

10.6.3Drivers and Barriers

10.7United Kingdom

10.7.1Forecast

10.7.2Key Events

10.7.3Drivers and Barriers

10.8Japan

10.8.1Forecast

10.8.2Key Events

10.8.3Drivers and Barriers

10.9China

10.9.1Forecast

10.9.2Key Events

10.9.3Drivers and Barriers

11Appendix

11.1Bibliography

11.2Abbreviations

11.3Methodology

11.4Forecasting Methodology

11.4.1Diagnosed Colorectal Cancer Patients

11.4.2Percent Drug-Treated Patients

11.4.3Drugs Included in Each Therapeutic Class

11.4.4Launch and Patent Expiration Dates

11.4.5General Pricing Assumptions

11.4.6Average Body Weight and Surface Area Across the 8MM

11.4.7Individual Drug Assumptions

11.4.8Generic Erosion

11.4.9Pricing of Pipeline Agents

11.5Primary Research – KOLs Interviewed for this Report

11.6Primary Research – Prescriber Survey

11.7About the Authors

11.7.1Analyst

11.7.2Epidemiologist

11.7.3Global Head of Healthcare

11.8About GlobalData

11.9Disclaimer

List of Tables

Table 1: TNM and Staging Classification System for CRC

Table 2: Symptoms of Colorectal Cancer

Table 3: Risk Factors and Comorbidities for CRC

Table 4: 8MM, Five-Year Relative Survival

Table 5: 8MM, Sources of CRC Incidence Data

Table 6: 8MM, Sources of CRC Diagnosed Five-Year Prevalent Cases Data

Table 7: 8MM, Sources of CRC Cancer Stage at Diagnosis Data

Table 8: 8MM, Diagnosed Incident Cases of CRC, Both Sexes, Ages =20 Years, N, 2013–2023

Table 9: 8MM, Age-Specific Diagnosed Incident Cases of CRC, Both Sexes, N, Row (%), 2013

Table 10: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, Ages =20 Years, 2013

Table 11: 8MM, Diagnosed Five-Year Prevalent Cases of CRC, Both Sexes, Ages =20 Years, N, 2013–2023

Table 12: 8MM, KRAS Status among CRC Prevalent Cases, 2013

Table 13: Treatment Guidelines for CRC

Table 14: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013

Table 15: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013

Table 16: Country Profile – US

Table 17: Country Profile – France

Table 18: Country Profile – Germany

Table 19: Country Profile – Italy

Table 20: Country Profile – Spain

Table 21: Country Profile – UK

Table 22: Country Profile – Japan

Table 23: Country Profile – China

Table 24: Leading Treatments for CRC, 2014

Table 25: Product Profile — Avastin

Table 26: Avastin SWOT Analysis, 2014

Table 27: Global Sales Forecast ($m) for Avastin, 2013-2023

Table 28: Product Profile — Erbitux

Table 29: Erbitux SWOT Analysis, 2014

Table 30: Global Sales Forecast ($m) for Erbitux, 2013-2023

Table 31: Product Profile – Vectibix

Table 32: Vectibix SWOT Analysis, 2014

Table 33: Global Sales Forecast ($m) for Vectibix, 2013-2023

Table 34: Product Profile – Stivarga

Table 35: Stivarga SWOT Analysis, 2014

Table 36: Global Sales Forecasts ($m) for Stivarga, 2013-2023

Table 37: Product Profile – Zaltrap

Table 38: Zaltrap SWOT Analysis, 2014

Table 39: Global Sales Forecasts ($m) for Zaltrap, 2013-2023

Table 40: Product Profile – Lonsurf

Table 41: Lonsurf SWOT Analysis, 2014

Table 42: Global Sales Forecasts ($m) for Lonsurf (TAS-102), 2013-2023

Table 43: Product Profile – TS-1

Table 44: TS-1 SWOT Analysis, 2014

Table 45: Global Sales Forecasts ($m) for TS-1, 2013-2023

Table 46: Product Profile – Xeloda

Table 47: Unmet Need and Opportunity in CRC

Table 48: Product Profile – Cyramza

Table 49: Cyramza SWOT Analysis, 2014

Table 50: Global Sales Forecasts ($m) for Cyramza, 2013-2023

Table 51: Product Profile – Imprime PGG

Table 52: Imprime PGG SWOT Analysis, 2014

Table 53: Global Sales Forecasts ($m) for Imprime PGG, 2013-2023

Table 54: Product Profile – MGN1703

Table 55: MGN1703 SWOT Analysis, 2014

Table 56: Global Sales Forecasts ($m) for MGN1703, 2013-2023

Table 57: Product Profile – Nintedanib

Table 58: Nintedanib SWOT Analysis, 2014

Table 59: Global Sales Forecasts ($m) for Nintedanib, 2013-2023

Table 60: Anti-Angiopoietin-2 Inhibitors in Development

Table 61: Early-stage Strategies for BRAF Mutation-Positive CRC

Table 62: Early-stage Strategies for KRAS Mutation-Positive CRC

Table 63: Anti-PD1 and Anti-PDL1 Drugs in Early-Stage Development for CRC

Table 64: Key Companies in the CRC Market in the 8MM, 2013-2023

Table 65: Roche’s CRC Portfolio Assessment, 2014

Table 66: Sanofi’s CRC Portfolio Assessment, 2014

Table 67: Eli Lilly’s CRC Portfolio Assessment, 2014

Table 68: Merck KGaA’s CRC Portfolio Assessment, 2014

Table 69: Bayer’s CRC Portfolio Assessment, 2014

Table 70: Taiho’s CRC Portfolio Assessment, 2014

Table 71: Sales Forecasts ($m) for Colorectal Cancer in the Global Markets, 2013-2023

Table 72: CRC Market Drivers and Barriers, 2014

Table 73: Sales Forecasts ($m) for Colorectal Cancer in the United States, 2013–2023

Table 74: Key Events Impacting Sales for CRC in the US, 2014

Table 75: US CRC Market Drivers and Barriers, 2014

Table 76: Sales Forecasts ($m) for Colorectal Cancer in France, 2013–2023

Table 77: Key Events Impacting Sales for CRC in France, 2014

Table 78: France CRC Market Drivers and Barriers, 2014

Table 79: Sales Forecasts ($m) for Colorectal Cancer in Germany, 2013–2023

Table 80: Key Events Impacting Sales for CRC in Germany, 2014

Table 81: Germany CRC Market Drivers and Barriers, 2014

Table 82: Sales Forecasts ($m) for Colorectal Cancer in Italy, 2013–2023

Table 83: Key Events Impacting Sales for CRC in Italy, 2014

Table 84: Italy CRC Market Drivers and Barriers, 2014

Table 85: Sales Forecasts ($m) for Colorectal Cancer in Spain, 2013–2023

Table 86: Key Events Impacting Sales for CRC in Spain, 2014

Table 87: Spain CRC Market Drivers and Barriers, 2014

Table 88: Sales Forecasts ($m) for Colorectal Cancer in the UK, 2013–2023

Table 89: Key Events Impacting Sales for CRC in the UK, 2014

Table 90: UK CRC Market – Drivers and Barriers, 2014

Table 91: Sales Forecasts ($m) for Colorectal Cancer in Japan, 2013–2023

Table 92: Key Events Impacting Sales for CRC in Japan, 2014

Table 93: Japan CRC Market – Drivers and Barriers, 2014

Table 94: Sales Forecasts ($m) for Colorectal Cancer in China, 2013–2023

Table 95: Key Events Impacting Sales for CRC in China, 2014

Table 96: China CRC Market – Drivers and Barriers, 2014

Table 97: Key Launch Dates

Table 98: Key Patent Expiries

Table 99: Average Body Weight and Surface Area Across the 8MM

Table 100: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Historical Age-Adjusted CRC Incidence (Cases per 100,000 Population) in 8MM, Men, 1998–2007

Figure 2: Historical Age-Adjusted CRC Incidence (Cases per 100,000 Population), in 8MM, Women, 1998–2007

Figure 3: 8MM, Diagnosed Incident Cases of CRC, Both Sexes, Ages =20 Years, N, 2013–2023

Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of CRC, Both Sexes, N, 2013

Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, Ages =20 Years, 2013

Figure 6: 8MM, Age-Standardized Incidence of CRC (Cases per 100,000 Population), Ages =20 Years, by Sex, 2013.

Figure 7: 8MM, Cancer Stage at Diagnosis Percentage Distribution, Ages =20 Years.

Figure 8: 8MM, Diagnosed Five-Year Prevalent Cases of CRC, Both Sexes, Ages =20 Years, N, 2013–2023

Figure 9: CRC – Phase III Pipeline

Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in CRC, 2013-2023

Figure 11: Clinical and Commercial Positioning of Cyramza

Figure 12: Clinical and Commercial Positioning of Imprime PGG

Figure 13: Clinical and Commercial Positioning of MGN1703

Figure 14: Clinical and Commercial Positioning of Nintedanib

Figure 15: Global Sales of Branded Products for Colorectal Cancer by Company, 2013–2023

Figure 16: Company Portfolio Gap Analysis in CRC, 2013–2023

Figure 17: Roche SWOT Analysis in CRC, 2014

Figure 18: Sanofi SWOT Analysis in CRC, 2014

Figure 19: Eli Lilly SWOT Analysis in CRC, 2014

Figure 20: Merck KGaA SWOT Analysis in CRC, 2014

Figure 21: Bayer SWOT Analysis in CRC, 2014

Figure 22: Taiho SWOT Analysis in CRC, 2014

Figure 23: Global Sales for Colorectal Cancer by Region, 2013–2023

Figure 24: Sales for Colorectal Cancer in the United States by Drug Class, 2013-2023

Figure 25: Sales for Colorectal Cancer in France by Drug Class, 2013-2023

Figure 26: Sales for Colorectal Cancer in Germany by Drug Class, 2013-2023

Figure 27: Sales for Colorectal Cancer in Italy by Drug Class, 2013-2023

Figure 28: Sales for Colorectal Cancer in Spain by Drug Class, 2013-2023

Figure 29: Sales for Colorectal Cancer in the United Kingdom by Drug Class, 2013–2023

Figure 30: Sales for Colorectal Cancer in Japan by Drug Class, 2013-2023

Figure 31: Sales for Colorectal Cancer in China by Drug Class, 2013-2023

$10995

Can be used by individual purchaser only

$32985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.